Cargando…
Modified recombinant human erythropoietin with potentially reduced immunogenicity
Recombinant human erythropoietin (rHuEPO) is a biopharmaceutical drug given to patients who have a low hemoglobin related to chronic kidney disease, cancer or anemia. However, some patients repeatedly receiving rHuEPO develop anti-rHuEPO neutralizing antibodies leading to the development of pure red...
Autores principales: | Susantad, Thanutsorn, Fuangthong, Mayuree, Tharakaraman, Kannan, Tit-oon, Phanthakarn, Ruchirawat, Mathuros, Sasisekharan, Ram |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810742/ https://www.ncbi.nlm.nih.gov/pubmed/33452310 http://dx.doi.org/10.1038/s41598-020-80402-1 |
Ejemplares similares
-
Intact mass analysis reveals the novel O-linked glycosylation on the stalk region of PD-1 protein
por: Tit-oon, Phanthakarn, et al.
Publicado: (2023) -
Prediction of the binding interface between monoclonal antibody m102.4 and Nipah attachment glycoprotein using structure-guided alanine scanning and computational docking
por: Tit-oon, Phanthakarn, et al.
Publicado: (2020) -
Prediction of the structural interface between fibroblast growth factor23 and Burosumab using alanine scanning and molecular docking
por: Kanhasut, Karnpob, et al.
Publicado: (2022) -
Generation of bispecific antibodies by structure-guided redesign of IgG constant regions
por: Iwasaki, Yordkhwan W., et al.
Publicado: (2023) -
Glycan–protein interactions in viral pathogenesis
por: Raman, Rahul, et al.
Publicado: (2016)